证券代码：603882 证券简称：金域医学 公告编号：2024-044 广州金域医学检验集团股份有限公司 2023 年年度 权益分派实施公告 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经广州金域医学检验集团股份有限公司（以下简称"公司"） 2024 年 5 月 20 日的 2023 年年度股东大会审议通过。 二、 分配方案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.88 元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2024/6/17 | － | 2024/6/18 | 2024/6/18 | 1. 发放年度：2023 年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《上海证券 ...

广州金域医学检验集团股份有限公司（以下简称"公司"）分别于 2024 年 4 月 25 日、2024 年 5 月 20 日召开第三届董事会第二十次会议、2023 年年度股东 大会，审议通过了《广州金域医学检验集团股份有限公司 2023 年度利润分配预 案》。公司 2023 年年度拟以实施权益分派股权登记日登记的总股本扣除公司回购 专用证券账户股份数为基数分配利润，拟向全体股东每股派发现金红利 0.88 元 （含税）。截至 2024 年 3 月 31 日,公司总股本 468,771,275 股，扣除公司回购专 用证券账户股份数 3,980,400 股后的基数为 464,790,875 股，以此计算本次合计 拟派发现金红利 409,015,970.00 元（含税）。 如在利润分配预案公告披露之日起至实施权益分派股权登记日期间，因可转 债转股、回购股份、股权激励授予股份回购注销或重大资产重组股份回购注销等 致使公司总股本或回购专用证券账户中的股份数量发生变动的，公司拟维持每股 现金分红总额：公司维持每股派发现金红利 0.88 元（含税）不变，派发现金 红利总额由 409,015,970.00 元（含税）调整为 40 ...

证券代码：603882 证券简称：金域医学 公告编号：2024-046 广州金域医学检验集团股份有限公司 关于控股股东、实际控制人部分股份补充质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 公司控股股东、实际控制人梁耀铭先生直接持有公司股份 74,191,907 股， 占公司总股本的 15.83%。本次补充质押股份 3,500,000 股，占梁耀铭先生直接 持有公司股份数的 4.72%，占公司总股本的 0.75%。 本次股份补充质押后，公司控股股东、实际控制人梁耀铭先生及其一致行 动人严婷女士、曾湛文先生以及梁耀铭先生控制的圣域钫、鑫镘域、圣铂域及 锐致累计质押 27,340,000 股，占其持有公司股份总数的 16.57%，占公司总股 本的 5.83%。 一、上市公司股份补充质押 广州金域医学检验集团股份有限公司（以下简称"公司"）控股股东、实际 控制人梁耀铭先生于 2023 年 4 月 4 日、2023 年 11 月 7 日及 2024 年 2 月 27 日 办理了部分股份质押手续（公告编号：2 ...

Investment Rating - Kingmed is downgraded to Neutral with a 12-month target price (TP) of Rmb41, down from Rmb75, indicating a 12.9% upside potential [1][24][20] - Dian Diagnostics maintains a Neutral rating with a revised TP of Rmb16, down from Rmb23, reflecting a 19.8% upside [1][24][20] - AmoyDx is rated as Buy with a target price of Rmb36, based on strong growth prospects in the cancer companion diagnostics market [1][28][20] Core Insights - The independent clinical laboratories (ICLs) are facing prolonged headwinds beyond the short-term impacts of Covid, including lower testing volumes, increased competition, and price cuts for diagnostic services [1][2][10] - The number of independent labs in China has surged from approximately 15,000 in 2019 to around 26,000 in 2023, intensifying competition in the market [2][10] - The anti-corruption campaign in healthcare is shifting diagnostics from outsourcing to in-hospital testing, benefiting companies like AmoyDx that focus on companion diagnostics [1][24][20] Summary by Sections Kingmed - Kingmed's revenue is projected to decline from Rmb15.5 billion in 2022 to Rmb8.3 billion in 2024, with a net profit of Rmb447 million expected in 2024 [1][32] - The company's gross profit margin (GPM) is anticipated to decrease due to a 30% price cut on average selling prices (ASP), which will reduce GPM by 4.3 percentage points [10][14] - Kingmed's market share is expected to remain stable despite the competitive pressures, but revenue and net profit estimates have been lowered due to declining total addressable market (TAM) [16][17] Dian Diagnostics - Dian's revenue is expected to decrease from Rmb13.4 billion in 2023 to Rmb13.0 billion in 2024, with a significant drop in net profit from Rmb663 million in 2023 to Rmb374 million in 2024 [1][35] - The company faces challenges from the loss of Covid-related business and increased competition, leading to a decline in GPM and NPM [27][24] - Dian's ability to leverage established relationships with hospitals gained during the Covid period is seen as a potential growth driver for its non-Covid testing business [27][24] AmoyDx - AmoyDx is projected to see a significant increase in the penetration rate of tumor companion diagnostics from 13% in 2020 to 45% by 2031, with expected revenue growth above 20% annually over the next decade [1][28] - The company's domestic sales reached Rmb785 million in FY23, reflecting a year-on-year growth of 23.65%, with in-hospital revenue growing over 40% [24][28] - AmoyDx's overseas business is also expanding, expected to contribute over 20% of its revenue by 2031 [1][28]

北京市中伦律师事务所 关于广州金域医学检验集团股份有限公司 2023 年年度股东大会的 法律意见书 二〇二四年五月 北京市朝阳区金和东路 20 号院正大中心 3 号南塔 22-31 层 邮编：100020 22-31/F, South Tower of CP Center, 20 Jin He East Avenue, Chaoyang District, Beijing l00020, P.R. China 电话/Tel : +86 10 5957 2288 传真/Fax : +86 10 6568 1022/1838 www.zhonglun.com 北京市中伦律师事务所 关于广州金域医学检验集团股份有限公司 2023 年年度股东大会的 法律意见书 致：广州金域医学检验集团股份有限公司 北京市中伦律师事务所（以下简称"本所"）作为广州金域医学检验集团股 份有限公司（以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席 公司 2023 年年度股东大会（以下简称"本次股东大会"）。本所律师根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上 ...

证券代码：603882 证券简称：金域医学 公告编号：2024-042 广州金域医学检验集团股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 注：截至本次股东大会股权登记日（2024 年 5 月 13 日），广州金域医学检验集团股份有限 公司（以下简称"公司"）总股本为 468,771,275 股，回购专用证券账户股份数为 5,363,900 股，因公司所持有的本公司股份没有表决权，故此次股东大会有表决权的股份总数为 463,407,375 股。 (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由董事会召集，公司董事长梁耀铭先生主持，本次会议的召集、召 开及表决形式均符合《公司法》及《公司章程》的规定。 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 1、出席会议的股东和代理人人数 56 2、出席会议的股东所持有表决权的股份总数（股） 288,358,86 ...

Investment Rating - The investment rating for the company is "Buy" [1][4][12] Core Views - The company achieved a revenue of 8.54 billion with a year-on-year decline of 44.82% in 2023, primarily due to reduced demand for COVID-19 testing services. However, the core medical testing business showed a same-caliber growth of 15% [1][5][12] - The company is focusing on enhancing its organizational structure and operational efficiency to improve competitiveness and resilience in a changing market environment [1][12] - The company has maintained a strong cash flow from operating activities, with a net cash flow of 1.23 billion, representing 191% of net profit [11][12] Financial Performance - In 2023, the company reported a net profit of 643 million, down 76.64% year-on-year, with a net profit margin of 4.3%, a decrease of 10.9 percentage points [1][9][14] - The gross profit margin for 2023 was 36.5%, down 6.6 percentage points, with increases in sales, management, and R&D expense ratios [9][10] - The company expects to recover its profitability as operational efficiency measures take effect, with projected net profits for 2024-2026 at 869 million, 1.08 billion, and 1.32 billion, respectively [12][14] Business Segments - The core medical testing revenue reached 7.73 billion in 2023, with a same-caliber growth of 15.35%, driven by significant demand in infectious diseases, neurological disorders, and cancer diagnostics [1][8][12] - The company launched 412 new projects in 2023, contributing to its innovation-driven growth strategy, with notable performance in high-end testing projects [12][14] Market Position - The company is positioned as a leader in the third-party medical testing sector, benefiting from cost advantages and scale effects, while continuously enhancing its market share in line with policy trends [12][14] - The current stock price corresponds to a price-to-earnings ratio of 19, 16, and 13 for the years 2024-2026, indicating a favorable valuation compared to industry peers [12][14]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 15% compared to the CSI 300 index in the next six months [1][8]. Core Insights - The company's short-term performance has been negatively impacted by external factors and impairment provisions, but future growth remains promising [3][4]. - In 2023, the company achieved a revenue of 85.40 billion RMB, a year-on-year decrease of 44.82%, primarily due to reduced testing demand related to public health events [2][4]. - The company's net profit for 2023 was 6.43 billion RMB, down 76.64% year-on-year, with a non-recurring net profit of 3.65 billion RMB, reflecting an 86.53% decline [2][4]. - The company plans to distribute a cash dividend of 0.88 RMB per share to all shareholders, which represents 77.56% of the net profit attributable to shareholders [2][4]. Financial Performance Summary - The company’s revenue for 2024 is projected to be 95.17 billion RMB, with a year-on-year growth rate of 11% [4][5]. - The net profit for 2024 is expected to be 7.33 billion RMB, reflecting a growth rate of 14% [4][5]. - The company’s gross profit margin decreased by 6.65 percentage points to 36.48% in 2023, while the overall net profit margin dropped by 10.91 percentage points to 7.46% [2][4]. - The company’s accounts receivable decreased from 70.25 billion RMB in 2022 to 53.35 billion RMB in 2023, indicating improved cash collection trends [3][4]. Business Growth and Strategy - The company’s core business is showing signs of recovery, with regular medical diagnostic service revenue increasing by 15.35% year-on-year to 77.26 billion RMB in 2023 [2][4]. - Significant growth was observed in key disease areas, with diagnostic services for neurological and psychiatric diseases growing by 30.32%, infectious diseases by 49.74%, and cardiovascular and endocrine diseases by 28.78% [2][4]. - The company has established 49 medical laboratories in mainland China and Hong Kong, with a focus on high-end market development, as evidenced by a 4.73 percentage point increase in revenue from tertiary hospital clients [2][4].

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company's revenue from routine medical testing reached 7.726 billion yuan in 2023, with a year-on-year growth of 15.35%. The proportion of revenue from tertiary hospitals increased significantly to 43.13%, up by 4.73 percentage points [6][7] - The company aims to improve profitability through cost reduction and efficiency enhancement, with a net profit margin of 7.46% in 2023, down by 10.91 percentage points year-on-year. The company reduced its workforce by 2,825 employees, a decrease of 19.60% year-on-year, which is expected to positively impact profitability in 2024 [6][7] Summary by Sections Financial Performance - In 2023, the company achieved a revenue of 8.540 billion yuan, a decrease of 44.82% year-on-year. The net profit attributable to shareholders was 643 million yuan, down 76.64% year-on-year. The operating cash flow was 1.231 billion yuan, down 36.81% year-on-year [5][8] - For Q1 2024, the company reported a revenue of 1.841 billion yuan, a year-on-year decrease of 13.05%, with a net profit of -19 million yuan [5][8] Revenue Breakdown - The company developed 412 new projects in 2023, contributing 6.38 billion yuan to total revenue, accounting for 7.47% of total revenue. Notable growth was seen in various diagnostic areas, including a 398.97% increase in revenue from infection tNGS series and a 525.35% increase in single-gene carrier screening [6][7] Profitability Outlook - The company is expected to improve its profitability in 2024 due to the gradual weakening of impairment losses and cost pressures from past expansions. The forecasted EPS for 2024-2026 is 1.80, 2.33, and 3.03 yuan, respectively, with corresponding P/E ratios of 22.0, 17.0, and 13.1 times [8][9]

证券代码：603882 证券简称：金域医学 公告编号：2024-041 本次业绩说明会以视频录播结合网络文字互动方式召开，公司将针对 2023 年度及 2024 年第一季度经营成果及财务指标的具体情况与投资者进行互动交流 和沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 1 会议召开时间：2024 年 5 月 16 日(星期四)15:00-16:00 会议召开地点：价值在线（www.ir-online.cn），投资者可访问网址 ht tps://eseb.cn/1ekC7X8LSEg 参会。 会议召开方式：视频录播结合网络文字互动 广州金域医学检验集团股份有限公司 关于召开 2023 年度暨 2024 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 问题征集方式：投资者可于 2024 年 5 月 15 日中午 12:00 前访问网址 h ttps://eseb.cn/1ekC7X8LSEg 进行会前提问，或将相关问题通过电子邮件 的形式发送至公司董事会办公室邮箱：si ...